Aneal Tenjarla

S.A.C. Capital Advisors seeks to invest in the stocks of companies with short-term growth catalysts. The firm employs quantitative techniques and merger arbitrage strategies.

Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements.

Functions as a College/University

Surveyor Capital is a global, multi-manager equities strategy and is one of Citadel’s three fundamental equities businesses. Their sector-aligned investment teams conduct deep fundamental research, developing an independent view on the companies they cover. They are specialists in their industries and experts in their coverage, building trusted relationships with many corporate management teams. The firm's investment teams leverage Citadel’s proprietary, market-neutral risk framework with the aim of building portfolios that minimize broad market exposures. Using this insight, they act on their investment theses and scale their risk-taking with confidence.

Sofinnova-IM primary focuses on (i) private venture related investments or (ii) equity related investments in public securities. Investments are generally made in biotechnology, pharmaceuticals and related industries. For its Venture Funds, the firm seeks to build a diverse and risk mitigated portfolio across stage, geography and equity market exposure. For its Public Fund, Sofinnova-IM seeks to deliver absolute returns across market cycles with the goal of capitalizing on significant sector inefficiency in the Therapeutics industry while exercising valuation discipline and focusing on risk management.